



# Market Announcement

16 October 2020

---

## PYC Therapeutics Limited (ASX: PYC) – Trading Halt (2+2)

### Description

The securities of PYC Therapeutics Limited ('PYC') will be placed in trading halt at the request of PYC, pending it releasing an announcement regarding a capital raising. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Thursday, 22 October 2020 or when the announcement is released to the market.

### Issued by

**Sandra Wutete**

Senior Adviser, Listings Compliance (Perth)

For personal use only

**16 October 2020**

## Request for Back to Back Trading Halts

In accordance with Listing Rule 17.1 and the Class Waiver under Listing Rule 18.1, PYC Therapeutics Limited ("PYC") requests that an immediate trading halt be placed on its securities pending the release of an announcement regarding a proposed capital raising that is material to the Company.

PYC anticipates that the back to back trading halts will be lifted on or before market open on Thursday 22 October 2020 by provision of an announcement to ASX regarding the capital raising.

PYC is not aware of any reason why the back to back trading halt should not be granted, nor of any other information relevant to this request.

This trading halt request has been approved by the Board of PYC Therapeutics Limited

**ENDS** For further information, please contact:

**INVESTORS**

Kaggen Ausma  
CBO  
info@pyctx.com

## About PYC Therapeutics

*PYC Therapeutics (ASX: PYC) is a drug development company solving a major challenge in the development of a revolutionary new class of drugs – delivering large drugs into cells. Cell Penetrating Peptides (CPPs) can overcome ‘the delivery challenge’ and provide access for a wide range of potent and precise drug ‘cargoes’ to the ‘undruggable genome’ – the highest value drug targets that exist inside cells. PYC Therapeutics is using its CPP platform to develop a pipeline of novel therapies with an initial focus on inherited retinal diseases.*

## Forward looking statements

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company’s control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company’s current intentions, plans, expectations and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

---

Tel: +61 8 6151 0994

[pyctx.com](http://pyctx.com)

**PYC Therapeutics Limited**

ACN 098 391 961